Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

IPSEN: Disclosure of Transactions in Own Shares Between 10/19/2020 And 10/20/2020

10/27/2020 | 12:01pm EST

Regulatory News:

Aggregated presentation by day and market

Issuer name

Issuer identification code

Transaction date

Identification code of the
financial instrument

Daily total volume (in
number of shares)

Daily weighted
average price of
shares acquired

Platform

IPSEN

549300M6SGDPB4Z94P11

19/10/2020

FR0010259150

9,596

78,0076

XPAR

IPSEN

549300M6SGDPB4Z94P11

19/10/2020

FR0010259150

3,883

77,9953

CHIX

IPSEN

549300M6SGDPB4Z94P11

19/10/2020

FR0010259150

1,061

78,0305

TRQX

IPSEN

549300M6SGDPB4Z94P11

19/10/2020

FR0010259150

1,167

77,9675

BATE

IPSEN

549300M6SGDPB4Z94P11

20/10/2020

FR0010259150

16,038

78,4253

XPAR

Total

31,745

78,2164

The information detailed by transaction and the buy-back objectives are available on the company's website at the following address:  http://www.ipsen.com/investors/regulated-information/


© Business Wire 2020
All news about IPSEN
03/02FUSION PHARMACEUTICALS  : to Buy Ipsen's Intellectual Property, Assets Related T..
MT
03/02IPSEN  : Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087,..
AQ
03/01IPSEN  : announces the arrival of Gwenan White, EVP Communications & Public Affa..
PU
03/01IPSEN  : receives positive CHMP opinion recommending Cabometyx in combination wi..
AQ
02/26IPSEN  : Wins EMA's Positive Opinion for Cabometyx With Opdivo in Kidney Cancer ..
MT
02/26BRISTOL MYERS : CHMP Backs Opdivo/Cabometyx in Advanced Renal Cell Carcinoma
DJ
02/26IPSEN  : Receives Positive CHMP Opinion Recommending Cabometyx® in Combination W..
BU
02/24IPSEN  : A new language inviting you to understand more about the rare disease c..
PU
02/22IPSEN  : announces new data from the Phase II CLARINET FORTE study which demonst..
AQ
02/22IPSEN  : Releases New Positive Data from Phase II Clarinet Forte Trial
MT
More news
Financials
Sales 2020 2 622 M 3 125 M 3 125 M
Net income 2020 462 M 550 M 550 M
Net Debt 2020 752 M 897 M 897 M
P/E ratio 2020 12,6x
Yield 2020 1,47%
Capitalization 5 782 M 6 888 M 6 892 M
EV / Sales 2020 2,49x
EV / Sales 2021 2,19x
Nbr of Employees 5 700
Free-Float 42,0%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 89,38 €
Last Close Price 70,00 €
Spread / Highest target 61,4%
Spread / Average Target 27,7%
Spread / Lowest Target 7,14%
EPS Revisions
Managers and Directors
NameTitle
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN3.09%6 888
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971